EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of olaparib on cyclophosphamide-induced ovarian tissue damage in patients with Breast Cancer 1 germline mutation

Joana Dias Nunes iD, Silvia Ottonello, Géraldine Van den Steen, Necati Findikli, Margherita Condorelli, Matteo Lambertini iD, Isabelle Demeestere iD

Reproduction · 04.11.2026 · 172 (5)

DOI: 10.1093/reprod/xaag138 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Reproduction, online erschienen am 29.10.2026. Verfasst von Joana Dias Nunes und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research Laboratory on Human Reproduction, Université Libre de Bruxelles (ULB), Brussels, Belgium. Hauptthemen laut MEDLINE: Phthalazines, Cyclophosphamide, Piperazines, Germ-Line Mutation. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Télévie, a grant of the Fonds National de la Recherche Scientifique-FNRS, Fonds Ithier-ULB, Italian Association for Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In brief: While Breast Cancer 1 (BRCA1) carriers might be more vulnerable to chemotherapy-induced gonadotoxicity, the fertility impact of poly (ADP-ribose) polymerase (PARP) inhibitors, which are now widely used in BRCA-associated breast cancer, remains unknown. This paper provides preliminary evidence that olaparib does not potentiate cyclophosphamide-induced ovarian damage. Abstract: Poly (ADP-ribose) polymerase (PARP) inhibitors are now used as adjuvant targeted therapy for in Breast Cancer 1 (BRCA1)-mutated breast cancer. Although prescribed to young women of reproductive age, their effects on fertility remain unknown, particularly when combined with highly gonadotoxic chemotherapy. This study therefore examined whether olaparib potentiates cyclophosphamide (CPA)-induced gonadotoxicity in human ovarian tissue. Cryopreserved ovarian tissue from young (<35 years) patients with breast cancer, with (n = 4) or without (n = 4) BRCA1 pathogenic variants, was exposed to anticancer drugs using two models: (i) a 3-day in-vitro culture with 4-hydroperoxycyclophosphamide (4HC; 10 µM) and/or olaparib (20 µM), and (ii) xenotransplantation in mice followed by one CPA injection (75 mg/kg) and 2 weeks of daily oral olaparib (100 mg/kg). Across both models and regardless of BRCA1 status, the proportion of primordial follicles remained unchanged following exposure to the drugs. However, in vivo, follicle density significantly reduced with CPA compared with controls in BRCA1-mutated xenografts. Olaparib did not exacerbate CPA-induced follicle loss. The 4HC induced DNA fragmentation and double-strand breaks in vitro in both groups, while olaparib alone caused minimal damage and did not appear to potentiate the effects of 4HC. In BRCA1-mutated xenografts, combined treatment resulted in a modest but significant reduction in RAD51 rates compared with controls, while 53BP1 expression tended to rise after CPA alone or combined with olaparib, without reaching significance. Our findings suggest that olaparib does not exacerbate CPA-induced gonadotoxicity, providing valuable information for reassuring patients regarding its reproductive safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhthalazinesCyclophosphamidePiperazinesGerm-Line MutationOvaryBreast NeoplasmsBRCA1 ProteinPoly(ADP-ribose) Polymerase InhibitorsAntineoplastic AgentsFemaleHumansAnimalsMiceAdultAntineoplastic Agents, Alkylating

Stichwörter der Autor:innen

BRCA1cyclophosphamidegonadotoxicityolaparibovarian tissue

Substanzen

olaparibPhthalazinesCyclophosphamidePiperazinesBRCA1 ProteinPoly(ADP-ribose) Polymerase InhibitorsBRCA1 protein, humanAntineoplastic Agents, AlkylatingAntineoplastic Agents

Autor:innen und Institutionen

  • Research Laboratory on Human Reproduction, Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy.
  • Fertility Clinic, HUB Erasme Hospital, Brussels, Belgium.
  • Academic Medical Oncology Unit, Ente Ospedaliero Ospedali Galliera, Genoa, Italy.

ORCID-Profile: Joana Dias Nunes, Matteo Lambertini, Isabelle Demeestere

Förderung

  • Télévie, a grant of the Fonds National de la Recherche Scientifique-FNRS
  • Fonds Ithier-ULB
  • Italian Association for Cancer Research
  • Télévie, a grant of the Fonds National de la Recherche Scientifique—FNRS

Zitieren

APA

Dias Nunes, J., Ottonello, S., Van den Steen, G., Findikli, N., Condorelli, M., Lambertini, M., & Demeestere, I. (2026). Effect of olaparib on cyclophosphamide-induced ovarian tissue damage in patients with Breast Cancer 1 germline mutation. Reproduction, 172(5). https://doi.org/10.1093/reprod/xaag138

Vancouver

Dias Nunes J, Ottonello S, Van den Steen G, Findikli N, Condorelli M, Lambertini M, et al. Effect of olaparib on cyclophosphamide-induced ovarian tissue damage in patients with Breast Cancer 1 germline mutation. Reproduction. 2026;172(5). doi:10.1093/reprod/xaag138

BibTeX
@article{DiasNunes2026,
  author = {Dias Nunes, Joana and Ottonello, Silvia and Van den Steen, Géraldine and Findikli, Necati and Condorelli, Margherita and Lambertini, Matteo and Demeestere, Isabelle},
  title = {Effect of olaparib on cyclophosphamide-induced ovarian tissue damage in patients with Breast Cancer 1 germline mutation},
  journal = {Reproduction},
  year = {2026},
  volume = {172},
  number = {5},
  doi = {10.1093/reprod/xaag138}
}
Kostenlos starten →